Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of 225Ac-J591 in Metastatic Castration-Resistant Prostate Cancer
NCT03276572Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2017
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CONV01-α in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Weill Cornell Medicine. Primary endpoints: Dose Limiting Toxicities at 8 weeks and Maximum Tolerated Dose at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
CONV01-α
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03276572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276572.